Coronavirus Vaccine Not Far Now, Scientists Develop Nanoparticle Vaccine

Coronavirus Vaccine Not Far Now, Scientists Develop Nanoparticle Vaccine

An experimental vaccine of Covid19 has been developed to provide ten times more protection from the antibodies of an infected coronavirus patient. Scientists at the University of Washington School of Medicine have had this success. It is a nanoparticle vaccine, whose initial testing was successful in mice. Now, this experimental vaccine will be human tested. This research is published in the journal Cell.

After the coronavirus-infected patients recover, antibodies are produced in their body, which helps the person to fight the virus attack again. In this research, the number of antibodies developed in the body by the nanoparticle vaccine that scientists have prepared is ten times more than the antibodies of the infected person. That is, antibodies produced by the dose of this experimental vaccine can fight against the virus with ten times more potency.

Researchers say the nanoparticle experimental vaccine they designed is ten times more potent than other potential vaccines for Coronavirus. The microscopic particles formed in it can attack the spike proteins of the coronavirus in large numbers and different ways. On the other hand, most of the potential vaccines for Covid19 are based on the spike protein present in the pointed exterior of the SARS-Cove-2 virus. Antibodies that develop in the body will not be as strong against that virus.

Citing data from studies on mice under the trial vaccine, the researchers said that it would also be effective on strains produced after mutations or mutations of the virus. Research has shown that after vaccination with this vaccine, the body produces a strong B-cell response. These B-cells are the memory cells of the body's immune system, which retain the experience of fighting the virus for a long time in the body. This keeps the body ready for a long time to fight the coronavirus or its other forms.

David Wessler, the lead author of this paper, said that even a small dose of this trial vaccine produces a high amount of antibodies in the body. Indeed, it is a structure-based vaccine, in which protein nanoparticles bind themselves. Thereby 60 receptors are released at a time, which binds themselves to the virus that enters the body. While such a large number of proteins are not released in the molecule-based structure, its low dose will also be effective.

Numerous Covid19 vaccines are being developed worldwide, but manufacturing, storage, and transporting them from one place to another is a big challenge. According to the researcher, only a low dose of this vaccine will give protection, which can also be kept outside the freezer, so its worldwide distribution will be easy and economical.